Roth Maintains Keryx (KERX) at 'Buy' Following Q2 Results; Long-Term Study Data Still Looks Good
Tweet Send to a Friend
Roth Capital maintains Keryx Biopharmaceuticals (Nasdaq: KERX) at Buy with a target price of $30 following Q2 results.Analyst Joseph Pantginis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
